Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy
Open Access
- 28 August 2022
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 22 (7) , 987-993
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Significance of Pathologic Response to Preoperative Therapy in Pancreatic CancerAnnals of Surgical Oncology, 2011
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunityCancer and Metastasis Reviews, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Cancer-related inflammationNature, 2008
- Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancerBlood, 2007
- One Thousand Consecutive PancreaticoduodenectomiesAnnals of Surgery, 2006
- Redefining the R1 resection in pancreatic cancerBritish Journal of Surgery, 2006
- Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitorsCancer Cell, 2005